Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma

Journal of Medical Economics

Volumn 14, Issue 2, 2011, Pages 245-252

  Alemao, Evo ^a,d   Rajagopalan, Srinivasan ^b   Yang, Shiyi ^a   Curiel, Rafael E ^a,d   Purvis, Joseph ^a,e   Al, Maiwenn J ^c  

^a PFIZER INC   (United States)

^b Med Data Analytics Inc   (United States)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d BRISTOL MYERS SQUIBB   (United States)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Health outcomes research; Inverse probability weighting; Quality adjusted survival; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; TEMSIROLIMUS;

ADULT; ADVANCED CANCER; ADVANCED RENAL CELL CARCINOMA; AGED; ARTICLE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 79953012393     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2011.566296     Document Type: Article

References (30)

1. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life oriented endpoint for comparing therapies. Biometrics 1989;45:781-795 (Pubitemid 19249321)
2. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. StatMed 1990;9:1259-76 (Pubitemid 20361738)
3. Zhao H, Tsiatis AA. Testing equality of survival functions of quality-adjusted lifetime. Biometrics 2001;57:861-867 (Pubitemid 32801183)
4. Shih W. Problems in dealing with missing data and informative censoring in clinical trials. Curr Control Trials Cardiovasc Med 2002;3:4
5. Fielding S, Maclennan G, Cook JA, et al. A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes. Trials 2008;9:51
6. Sprangers MAG, Moinpour CM, Moynihan TJ, et al. Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clin Proc 2002;77:561-71 (Pubitemid 34587346)
7. Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med 1998;17:517-32 (Pubitemid 28118924)
8. Fielding S, Fayers PM, Ramsay CR. Investigating the missing data mechanism in quality of life outcomes: a comparison of approaches. Health Qual Life Outcomes 2009;7:57
9. Rubin DB. Inference and missing data. Biometrika 1976;63:581-92
10. Schafer JL. Analysis of Incomplete Multivariate Data. Monographs on Statistics and Applied Probability 72. New York: Chapman & Hall, 1997
11. Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ 2005;14:763-76 (Pubitemid 41093974)
12. Allison PD. Missing data. Sage University Papers Series on Quantitative Applications in the Social Sciences, 07-136. Thousand Oaks, CA: Sage Publications Inc., 2001
13. Lin DY, Feuer EJ, Etzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-34 (Pubitemid 27262208)
14. Zhao H, Tsiatis AA. A consistent estimator for the distribution of quality adjusted survival time. Biometrika 1997;84:339-48
15. Willan AR, Lin DY, Cook RJ, et al. Using inverse-weighing in cost-effectiveness analysis with censored data. Stat Methods Med Res 2002; 11:539-51 (Pubitemid 36104144)
16. Willan AR, Briggs AH. Statistical Analysis of Cost-Effectiveness Data. Chichester, UK: Wiley, 2006:38-40
17. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81 (Pubitemid 46849157)
18. Torisel® [package insert]. Philadelphia, PA: Pfizer Inc., 2010. Available at: http://labeling.pfizer.com/showlabeling.aspx?ID=490. Accessed March 1, 2011
19. Roferon-A® [package insert]. Nutley, NJ: Hoffman-La Roche Inc., 2008. Available at http://www.gene.com/gene/products/information/roferon-a/pdf/pi. pdf. Accessed March 1, 2011
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
21. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell car-cinoma. J Clin Oncol 2002;20:289-96 (Pubitemid 34032623)
22. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-40 (Pubitemid 29368255)
23. Mekhail TM, Abou-Jawde RM, BouMerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832-41 (Pubitemid 46224183)
24. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
25. Oppe M, Rabin R, de Charro F. EQ-5D User Guide, Version 1.0. Rotterdam: The EuroQol Group, 2008
26. National Cancer Institute. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0. 2006. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf. Accessed March 1, 2011
27. Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19:1387-92
28. Wang H, Zhao H. Regression analysis of mean quality-adjusted lifetime with censored data. Biostatistics 2007;8:368-82 (Pubitemid 46569597)
29. Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med 2005; 24:3089-110 (Pubitemid 41489423)
30. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60 (Pubitemid 30660034)